NEUROBLASTOMA RECURRENT
Clinical trials for NEUROBLASTOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new NEUROBLASTOMA RECURRENT trials appear
Sign up with your email to follow new studies for NEUROBLASTOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to stall childhood cancers
Disease control Recruiting nowThis study tests a new oral drug, AMXT 1501, combined with another drug called DFMO for children and young adults (up to age 21) with certain cancers like neuroblastoma, brain tumors, and sarcomas. The first part finds the safest dose, and the second part checks if the combo help…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for tough childhood cancer: immune booster joins fight against relapsed neuroblastoma
Disease control Recruiting nowThis study tests whether adding an experimental immune-boosting drug (N-803) to standard chemo-immunotherapy can help children and young adults (under 30) with neuroblastoma that has come back or not responded to treatment. About 54 participants will receive the combination to se…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New 4-drug combo offers hope for kids with relapsed neuroblastoma
Disease control Recruiting nowThis study tests a combination of four immune-based treatments for children whose neuroblastoma has returned or not responded to standard therapy. The treatment includes natural killer cells, an antibody, two immune-boosting proteins, and a drug that activates a special receptor.…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE2 • Sponsor: Hong Kong Children's Hospital • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Promising combo therapy for childhood cancers enters human trials
Disease control Recruiting nowThis study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated May 18, 2026 12:00 UTC